Mohammad Rubayet Hasan

Mohammad Rubayet Hasan

Auto-generated profile, based on publicly available information

Mohammad Rubayet Hasan

Affiliations Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada, Research Institute of St. Joe’s Hamilton, Hamilton, Canada, Hamilton Regional Laboratory Medicine Program, Hamilton, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PTPatrick Tang
Patrick Tang
MHMohammad R. Hasan
Mohammad R. Hasan
HCHiam Chemaitelly
Hiam Chemaitelly
HYHADI YASSINE
HADI YASSINE
FBFatiha Benslimane
Fatiha Benslimane
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad

9 July 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HCHiam Chemaitelly
Hiam Chemaitelly
HYHADI YASSINE
HADI YASSINE
FBFatiha M. Benslimane
Fatiha M. Benslimane
HKHebah A. Al Khatib
Hebah A. Al Khatib
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad

1 April 2016 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
MHMohammad R. Hasan
Mohammad R. Hasan
ARArun Rawat
Arun Rawat
PTPatrick Tang
Patrick Tang
PJPuthen Veettil Jithesh
Puthen Veettil Jithesh
ETEva Thomas
Eva Thomas
PTPeter Tilley
Peter Tilley
Next-generation sequencing (NGS) technology has shown promise for the detection of human pathogens from clinical samples. However, one of the major obstacles to the use of NGS in diagnostic microbiology is the low ratio of pathogen DNA to human DNA in most clinical specimens. In this study, we aimed to develop a specimen-processing protocol to remove human DNA and enrich specimens for bacterial and viral DNA for shotgun metagenomic sequencing. Cerebrospinal fluid (CSF) and nasopharyngeal aspirate (NPA) specimens, spiked with control bacterial and viral pathogens, were processed using either a commercially available kit (MolYsis) or various detergents followed by DNase prior to the extraction of DNA. Relative quantities of human DNA and pathogen DNA were determined by real-time PCR. The MolYsis kit did not improve the pathogen-to-human DNA ratio, but significant reductions (>95%; P < 0.001) in human DNA with minimal effect on pathogen DNA were achieved in samples that were treated with 0.025% saponin, a nonionic surfactant. Specimen preprocessing significantly decreased NGS reads mapped to the human genome ( P < 0.05) and improved the sensitivity of pathogen detection ( P < 0.01), with a 20- to 650-fold increase in the ratio of microbial reads to human reads. Preprocessing also permitted the detection of pathogens that were undetectable in the unprocessed samples. Our results demonstrate a simple method for the reduction of background human DNA for metagenomic detection for a broad range of pathogens in clinical samples.

30 September 2015 in Metabolites
Verified
Journal Article
Open access
PDF file
MRMahbuba Rahman
Mahbuba Rahman
MHMohammad Rubayet Hasan
Mohammad Rubayet Hasan
Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA) in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs.

23 July 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
MHMohammad Rubayet Hasan
Mohammad Rubayet Hasan
MSMohammed Suleiman
Mohammed Suleiman
APAndrés Pérez-López
Andrés Pérez-López
Coronavirus disease 2019 (COVID-19) pandemic triggered an unprecedented global effort in developing rapid and inexpensive diagnostic and prognostic tools. Since the genome of SARS-CoV-2 was uncovered, detection of viral RNA by RT-qPCR has played the most significant role in preventing the spread of the virus through early detection and tracing of suspected COVID-19 cases and through screening of at-risk population. However, a large number of alternative test methods based on SARS-CoV-2 RNA or proteins or host factors associated with SARS-CoV-2 infection have been developed and evaluated. The application of metabolomics in infectious disease diagnostics is an evolving area of science that was boosted by the urgency of COVID-19 pandemic. Metabolomics approaches that rely on the analysis of volatile organic compounds exhaled by COVID-19 patients hold promise for applications in a large-scale screening of population in point-of-care (POC) setting. On the other hand, successful application of mass-spectrometry to detect specific spectral signatures associated with COVID-19 in nasopharyngeal swab specimens may significantly save the cost and turnaround time of COVID-19 testing in the diagnostic microbiology and virology laboratories. Active research is also ongoing on the discovery of potential metabolomics-based prognostic markers for the disease that can be applied to serum or plasma specimens. Several metabolic pathways related to amino acid, lipid and energy metabolism were found to be affected by severe disease with COVID-19. In particular, tryptophan metabolism via the kynurenine pathway were persistently dysregulated in several independent studies, suggesting the roles of several metabolites of this pathway such as tryptophan, kynurenine and 3-hydroxykynurenine as potential prognostic markers of the disease. However, standardization of the test methods and large-scale clinical validation are necessary before these tests can be applied in a clinical setting. With rapidly expanding data on the metabolic profiles of COVID-19 patients with varying degrees of severity, it is likely that metabolomics will play an important role in near future in predicting the outcome of the disease with a greater degree of certainty.

27 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
PTPatrick Tang
Patrick Tang
PCPeter Coyle
Peter Coyle
RBRoberto Bertollini
Roberto Bertollini
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold (Ct) value is inversely correlated with viral load and culturable virus. Here, we investigate differences in RT-qPCR Ct values across Qatar’s national cohorts of primary infections, reinfections, BNT162b2 (Pfizer-BioNTech) breakthrough infections, and mRNA-1273 (Moderna) breakthrough infections. Our matched-cohort analyses of the randomly diagnosed infections show higher mean Ct value in all cohorts of breakthrough infections compared to the cohort of primary infections in unvaccinated individuals. The Ct value is 1.3 (95% CI: 0.9–1.8) cycles higher for BNT162b2 breakthrough infections, 3.2 (95% CI: 1.9–4.5) cycles higher for mRNA-1273 breakthrough infections, and 4.0 (95% CI: 3.5–4.5) cycles higher for reinfections in unvaccinated individuals. Since Ct value correlates inversely with SARS-CoV-2 infectiousness, these differences imply that vaccine breakthrough infections and reinfections are less infectious than primary infections in unvaccinated individuals. Public health benefits of vaccination may have been underestimated, as COVID-19 vaccines not only protect against acquisition of infection, but also appear to protect against transmission of infection.